Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang, Eugene J Mark, Julie M Batten, Haiquan Chen, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, David P Carbone, Hongbin Ji, Jeffrey A Engelman, Mari Mino-Kenudson, William Pao, A John Iafrate. J Clin Oncol 2012
Times Cited: 1041
Times Cited: 1041
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari, S C Wang, K D Wilner, J W Clark, S-H I Ou. Ann Oncol 2019
Times Cited: 134
Times Cited: 134
List of shared articles
Times cited
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C Cappelleri, D Ross Camidge. Future Oncol 2022
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C Cappelleri, D Ross Camidge. Future Oncol 2022
Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
Xuehua Xie, Mengxing You, Erhong Meng, Shunyou Wang, Beifang Niu, Weiming Huang. J Cancer Res Clin Oncol 2022
Xuehua Xie, Mengxing You, Erhong Meng, Shunyou Wang, Beifang Niu, Weiming Huang. J Cancer Res Clin Oncol 2022
Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib.
Lu Chen, Lixian Li, Wanyi Chen. Clin Pharmacol Drug Dev 2022
Lu Chen, Lixian Li, Wanyi Chen. Clin Pharmacol Drug Dev 2022
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan.
Hsiang-Sheng Wang, Chien-Ying Liu, Sheng-Chi Hsu, Shih-Chiang Huang, Tsai-Hsien Hung, Kwai-Fong Ng, Tse-Ching Chen. Int J Mol Sci 2022
Hsiang-Sheng Wang, Chien-Ying Liu, Sheng-Chi Hsu, Shih-Chiang Huang, Tsai-Hsien Hung, Kwai-Fong Ng, Tse-Ching Chen. Int J Mol Sci 2022
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, Jan Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, Sylvia Gütz, Daniel C Christoph, Eckart Laack,[...]. Ther Adv Med Oncol 2021
Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, Jan Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, Sylvia Gütz, Daniel C Christoph, Eckart Laack,[...]. Ther Adv Med Oncol 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.
Yoon Jung Jang, Dong-Gon Hyun, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji, Jae Cheol Lee. BMC Cancer 2021
Yoon Jung Jang, Dong-Gon Hyun, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji, Jae Cheol Lee. BMC Cancer 2021
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D Imbusch, Eray Goekkurt, Sonja Loges. Oncol Res Treat 2021
Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D Imbusch, Eray Goekkurt, Sonja Loges. Oncol Res Treat 2021
Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.
Maisam Makarem, Doreen A Ezeife, Adam C Smith, Janice J N Li, Jennifer H Law, Ming-Sound Tsao, Natasha B Leighl. Curr Oncol 2021
Maisam Makarem, Doreen A Ezeife, Adam C Smith, Janice J N Li, Jennifer H Law, Ming-Sound Tsao, Natasha B Leighl. Curr Oncol 2021
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Juan Li, Qifeng Wang, Jun Ge, Yuke Tian, Wenxiu Yao. Oncologist 2021
Juan Li, Qifeng Wang, Jun Ge, Yuke Tian, Wenxiu Yao. Oncologist 2021
Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer.
Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel. Front Med (Lausanne) 2021
Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel. Front Med (Lausanne) 2021
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Jaclyn M Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K W Chan. BMC Cancer 2021
Jaclyn M Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K W Chan. BMC Cancer 2021
ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer.
Daniel Almquist, Vinicius Ernani. JCO Oncol Pract 2021
Daniel Almquist, Vinicius Ernani. JCO Oncol Pract 2021
Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer.
Jiangping Yang, Ping Zhou, Min Yu, Yan Zhang. Front Oncol 2021
Jiangping Yang, Ping Zhou, Min Yu, Yan Zhang. Front Oncol 2021